Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 1,772 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $16.49, for a total transaction of $29,220.28. Following the completion of the sale, the chief executive officer now owns 9,283 shares in the company, valued at $153,076.67. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Craig A. Wheeler also recently made the following trade(s):
- On Friday, November 8th, Craig A. Wheeler sold 2,601 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.16, for a total transaction of $42,032.16.
Shares of Momenta Pharmaceuticals stock traded down $0.14 during trading on Friday, hitting $15.91. 24,481 shares of the company’s stock traded hands, compared to its average volume of 503,446. The firm’s fifty day moving average price is $14.42 and its 200 day moving average price is $12.87. Momenta Pharmaceuticals, Inc. has a twelve month low of $9.51 and a twelve month high of $16.90. The company has a market cap of $1.63 billion, a PE ratio of -7.82 and a beta of 2.07.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.09). Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The business had revenue of $6.40 million for the quarter, compared to analyst estimates of $5.24 million. During the same quarter last year, the firm posted ($0.65) earnings per share. Momenta Pharmaceuticals’s revenue was down 57.0% on a year-over-year basis. As a group, research analysts predict that Momenta Pharmaceuticals, Inc. will post -2.58 EPS for the current year.
Institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its position in shares of Momenta Pharmaceuticals by 2.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 572,669 shares of the biotechnology company’s stock valued at $7,130,000 after acquiring an additional 14,274 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Momenta Pharmaceuticals by 43.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 64,000 shares of the biotechnology company’s stock valued at $791,000 after acquiring an additional 19,490 shares in the last quarter. State of Tennessee Treasury Department lifted its holdings in Momenta Pharmaceuticals by 9.4% during the 3rd quarter. State of Tennessee Treasury Department now owns 71,810 shares of the biotechnology company’s stock valued at $931,000 after purchasing an additional 6,169 shares during the last quarter. Fosun International Ltd bought a new position in Momenta Pharmaceuticals during the 2nd quarter valued at about $1,130,000. Finally, Atria Investments LLC bought a new position in Momenta Pharmaceuticals during the 2nd quarter valued at about $1,518,000. Institutional investors and hedge funds own 96.11% of the company’s stock.
Several analysts have issued reports on MNTA shares. SunTrust Banks started coverage on shares of Momenta Pharmaceuticals in a research report on Tuesday. They issued a “buy” rating and a $29.00 price target on the stock. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 31st. Piper Jaffray Companies set a $35.00 price target on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Stifel Nicolaus restated a “buy” rating and issued a $29.00 price target on shares of Momenta Pharmaceuticals in a research report on Thursday, October 24th. Finally, Wells Fargo & Co assumed coverage on shares of Momenta Pharmaceuticals in a research report on Wednesday, November 6th. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Momenta Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $23.45.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Read More: Dividend
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.